Mucosal vaccination against encapsulated respiratory bacteria - New potentials for conjugate vaccines?

Scandinavian Journal of Immunology

Volumn 58, Issue 2, 2003, Pages 119-128

  Jakobsen, H ^a   Jonsdottir, I ^a,b  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b UNIVERSITY OF ICELAND   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CHOLERA TOXIN; DIPHTHERIA TOXIN; ESCHERICHIA COLI ENTEROTOXIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; LIPOPOLYSACCHARIDE; MENINGOCOCCUS VACCINE; ORAL POLIOMYELITIS VACCINE; OUTER MEMBRANE PROTEIN; PNEUMOCOCCUS VACCINE; SECRETORY IMMUNOGLOBULIN; STREPTOCOCCUS VACCINE; TETANUS TOXOID; VIRULENCE FACTOR;

ADULT; ANIMAL MODEL; ANTIBODY RESPONSE; BACTERIAL INFECTION; BACTERIAL VIRULENCE; CHILD; CONTROLLED STUDY; CPG ISLAND; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INFANT; MUCOSAL IMMUNITY; NEISSERIA MENINGITIDIS; NEWBORN; NONHUMAN; OTITIS MEDIA; POLIOMYELITIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE; TUBERCULOSIS; VACCINATION; VIRUS INFECTION;

ADULT; BACTERIAL VACCINES; CHILD; HAEMOPHILUS INFECTIONS; HAEMOPHILUS VACCINES; HUMANS; IMMUNITY, MUCOSAL; INFANT; NEISSERIACEAE INFECTIONS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; RESPIRATORY TRACT INFECTIONS; VACCINES, CONJUGATE;

EID: 0041346181     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2003.01292.x     Document Type: Review

References (157)

1. Falla TJ, Dobson SR, Crook DW et al. Population-based study of non-typable Haemophilus influenzae invasive disease in children and neonates. Lancet 1993;341:851-4.
2. Booy R, Hodgson SA, Slack MP, Anderson EC, Mayon-White RT, Moxon ER. Invasive Haemophilus influenzae type b disease in the Oxford region (1985-91). Arch Dis Child 1993;69:225-8.
3. Dajani AS, Asmar BI, Thirumoorthi MC. Systemic Haemophilus influenzae disease: an overview. J Pediatr 1979;94:355-64.
4. Losonsky GA, Santosham M, Sehgal VM, Zwahlen A, Moxon ER. Haemophilus influenzae disease in the White Mountain. Apaches: molecular epidemiology of a high risk population. Pediatr Infect Dis J 1984;3:539-47.
5. Ward JI, Lum MK, Hall DB, Silimperi DR, Bender TR. Invasive Haemophilus influenzae type b disease in Alaska: background epidemiology for a vaccine efficacy trial. J Infect Dis 1986;153:17-26.
6. Faden H, Brodsky L, Bernstein J et al. Otitis media in children: local immune response to nontypeable Haemophilus influenzae. Infect Immun 1989;57:3555-9.
7. Olson L, Jackson M. Only the pneumococcus. Pediatr Infect Dis J 1999;18:850.
8. Dagan R, Musher D. Is the pneumococcus the one and only in acute otitis media? Pediatr Infect Dis J 2000;19:400.
9. Jokinen C, Heiskanen L, Juvonen H et al. Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern Finland. Clin Infect Dis 2001;32:1141-54.
10. Shann F. Etiology of severe pneumonia in children in developing countries. Pediatr Infect Dis J 1986;5:247-52.
11. Juven T, Mertsola J, Waris M et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J 2000;19:293-8.
12. Adegbola RA, Obaro SK. Diagnosis of childhood pneumonia in the tropics. Ann Trop Med Parasitol 2000;94:197-207.
13. Gold R. Epidemiology of bacterial meningitis. Infect Dis Clin North Am 1999;13:515-25.
14. Schuchat A, Robinson K, Wenger JD et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 1997;337:970-6.
15. Organization WHO. Programme for the control of acute respiratory infections: pneumococcal conjugate vaccines. Geneva, Switzerland: WHO, 1994.
16. Hausdorff WP, Siber G, Paradiso PR. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet 2001;357:950-2.
17. Cartwright K, Noah N, Peltola H. Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000. Vaccine 2001;19:4347-56.
18. Rosenstein NE, Fischer M, Tappero JW. Meningococcal vaccines. Infect Dis Clin North Am 2001;15:155-69.
19. Hoyert DL, Kochaneck KD, Murphy SL. Deahts: final data for national vital statistics reports. Atlanta: Centers for Diesase Control and Prevention, 1999, 55-7.
20. Schuchat A. Group B Streptococcus. Lancet 1999;353:51-6.
21. Paoletti LC, Wessels MR, Rodewald AK, Shroff AA, Jennings HJ, Kasper DL. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun 1994;62:3236-43.
22. Bruyn GA, Zegers BJ, Van Furth R. Mechanisms of host defense against infection with Streptococcus pneumoniae. Clin Infect Dis 1992;14:251-62.
23. Musher DM, Chapman AJ, Goree A, Jonsson S, Briles DE, Baughn E. Natural and vaccine-related immunity to Streptococcus pneumoniae. J Infect Dis 1986;154:245-56.
24. AlonsodeVelasco E, Verheul AFM, Verhoef J, Snippe H. Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol Rev 1995;59:591-603.
25. Winkelstein JA. The role of complement in the host's defense against Streptococcus pneumoniae. Rev Infect Dis 1981;3:289-98.
26. Winkelstein JA, Moxon ER. The role of complement in the host's defense against Haemophilus influenzae. J Infect Dis 1992;165 (Suppl. 1):S62-5.
27. Frank MM. The mechanism by which microorganisms avoid complement attack. Curr Opin Immunol 1992;4:14-9.
28. Shapiro ED, Berg AT, Austrian R et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-60.
29. Hedlund JU, Kalin ME, Ortqvist AB, Henrichsen J. Antibody response to pneumococcal vaccine in middle-aged and elderly patients recently treated for pneumonia. Arch Intern Med 1994;154:1961-5.
30. Baker CJ, Kasper DL. Group B streptococcal vaccines. Rev Infect Dis 1985;7:458-67.
31. Baker CJ, Rench MA, Edwards MS, Carpenter RJ, Hays BM, Kasper DL. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. N Engl J Med 1988; 319:1180-5.
32. Steinhoff MC, Edwards K, Keyserling H, Thoms ML, Madore D. Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines. Pediatr Infect Dis J 1996;15:425-30.
33. Konradsen HB. Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons. Clin Infect Dis 1995;21:616-20.
34. Peltola H, Kayhty H, Sivonen A, Makela H. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccines 3 months to 5 years of age in Finland. Pediatrics 1977;60:730-7.
35. Douglas RM, Paton JC, Duncan SJ, Hansman DJ. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 1983;148:131-7.
36. Smith DH, Peter G, Ingram DL, Harding AL, Anderson P. Responses of children immunized with the capsular polysaccharide of Hemophilus influenzae, type b. Pediatrics 1973;52:637-44.
37. Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2. Annu Rev Immunol 1995;13:655-92.
38. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992;165:S49-S52.
39. Mond JJ, Vos Q, Lees A, Snapper CM. T cell independent antigens. Curr Opin Immunol 1995;7:349-54.
40. Ishioka GY, Lamont AG, Thomson D et al. MHC interaction and T cell recognition of carbohydrates and glycopeptides. J Immunol 1992;148:2446-51.
41. Harding CV, Roof RW, Allen PM, Unanue ER. Effect of pH and polysaccharides on peptide binding to class II major histocompatibility complex molecules. Proc Natl Acad Sci USA 1991; 88: 2740-4.
42. Goebel W, Avery OT. Chemo-immunological studies on conjugated carbohydrate proteins. I. The synthesis of p-aminophenol b-glucoside, p-aminophenol b-galactoside and their coupling with serum globulin. J Exp Med 1929;50:521-33.
43. Siber GR. Pneumococcal disease: prospects for a new genetation of vaccines. Science 1994;265:1385-7.
44. Robbins JB, Schneerson R. Polysaccharide-protein conjugates: a new generation of vaccines. J Infect Dis 1990;161:821-32.
45. Becker RS. Conjugate vaccines: practice and theory. Springer Semin Immunopathol 1993;15:217-26.
46. Eskola J, Käyhty H, Peltola H et al. Antibody levels achieved in infants by course of Haemophilus influenzae type B polysaccharide/diphtheria toxoid conjugate vaccine. Lancet 1985;1:1184-6.
47. Eskola J, Käyhty H, Takala AK. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 1990;323:1381-7.
48. Black SB, Shinefield H, Fireman B, Hiatt R, olen M, Vittinghoff E. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J 1991;10:97-104.
49. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000;30:100-21.
50. Wuorimaa T, Kayhty H. Current state of pneumococcal vaccines. Scand J Immunol 2002;56:111-29.
51. Åhman H, Käyhty H, Lehtonen H, Leroy O, Froeschle J, Eskola J. Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr Infect Dis J 1998;17:211-6.
52. Obaro SK, Huo Z, Banya WA et al. A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children. Pediatr Infect Dis J 1997;16:1135-40.
53. Dagan R, Melamed R, Muallem M et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996;174:1271-8.
54. Dagan R, Givon-Lavi N, Zamir O et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis 2002;185:927-36.
55. Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19:187-95.
56. Shinefield H, Black S, Ray P, Fireman B, Schwallbe J, Lewis E. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J 2002;21:182-6.
57. Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001;344:403-9.
58. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001;20 (Suppl. 1):S58-67.
59. Balmer P, Miller E. Meningococcal disease: how to prevent and how to manage. Curr Opin Infect Dis 2002;15:275-81.
60. Leach A, Twumasi PA, Kumah S et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 1997;175:200-4.
61. Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001;357:195-6.
62. Kasper DL, Paoletti LC, Wessels MR et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 1996;98:2308-14.
63. Baker CJ, Paoletti LC, Rench MA et al. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. J Infect Dis 2000;182:1129-38.
64. Kotloff KL, Fattom A, Basham L, Hawwari A, Harkonen S, Edelman R. Safety and immunogenicity of a tetravalent group B streptococcal polysaccharide vaccine in healthy adults. Vaccine 1996;14:446-50.
65. Baker CJ, Rench MA, McInnes P. Immunization of pregnant women with group B streptococcal (GBS) type III caspular polysaccharide (CPS)-tetanus toxoid (III-TT) conjugate vaccine. In: Protection of Newborns Through Maternal Immunization. France: Les Pensiéres, 2002.
66. Brandtzaeg P, Bersrad AE, Farstad IN et al. Mucosal immunity - A major adaptive defence mechanism. Behring Inst Mitt 1997;98:1-23.
67. Brandtzaeg P, Baekkevold ES, Farstad IN et al. Regional specialization in the mucosal immune system: what happens in the microcompartments. Immunol Today 1999;20:141-51.
68. McGhee JR, Mestecky J, Dertzbaugh MT, Eldrige JH, Hirasawa M, Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 1992;10:75-88.
69. Modlin JF. Mucosal immunity following oral poliovirus vaccine and enhanced potency inactivated poliovirus vaccine immunization. Pediatr Infect Dis J 1991;10:976-8.
70. Plotkin SA. Current issues in evaluating the efficacy of oral poliovirus vaccine and inactivated poliovirus vaccine immunization. Pediatr Infect Dis J 1991;10:979-81.
71. Ogra PA, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 2001;14:430-45.
72. Spangler BD. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol Rev 1992;56: 622-47.
73. Elson CO, Ealding W. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol 1984;132:2736-41.
74. Elson CO, Ealding W. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J Immunol 1984;133:2892-7.
75. Clements JD, Hartzog NM, Lyon FL. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 1988;6:269-77.
76. Millar DG, Hirst TR, Snider DP. Esherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its closely related homologue, the B subunit of cholera toxin. Infect Immun 2001;69:3476-82.
77. Douce G, Turcotte C, Cropley I et al. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci USA 1995; 92:1644-8.
78. Lycke N, Tsuji T, Holmgren J. The adjuvant effect of Vibrio cholerae and Eschericia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol 1992;22:2277-81.
79. Del Giudice G, Rappuoli R. Genetically derived toxoids for use as vaccines and adjuvants. Vaccine 1999;17:S44-S52.
80. Pizza M, Giuliani MM, Fontana MR et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 2001;19:2534-41.
81. Rappuoli R, Douce G, Dougan G, Pizza M. Genetic detoxification of bacterial toxins: a new approach to vaccine development. Int Arch Allergy Immunol 1995;108:327-33.
82. Williams NA, Hirst TR, Nashar TO. Immune modulation b y the cholera-like enterotoxins: from adjuvant to therapeutic. Immunol Today 1999;20:95-101.
83. Simmons CP, Ghaem-maghami M, Petrovska L et al. Immunomodulation using bacterial enterotoxins. Scand J Immunol 2001;53:218-26.
84. Bromander A, Holmgren J, Lycke N. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J Immunol 1991;146:2908-14.
85. Matousek MP, Nedrud JG, Harding CV. Distinct effects of recombinant cholera toxin B subunit and holotoxin on different stages of class II MHC antigen processing and presentation by macrophages. J Immunol 1996;156:4137-45.
86. Nashar TO, Hirst TR, Williams NA. Modulation of B-cell activation by the B subunit of Escherichia coli enterotoxin: receptor interaction up-regulates MHC class II, B7, CD40, CD25 and ICAM-1. Immunology 1997;91:572-8.
87. Aagren LC, Ekman L, Lowenadler B, Lycke NY. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J Immunol 1997;158:3936-46.
88. Yamamoto M, Kiyono H, Kweon M et al. Enterotoxin adjuvants have direct effects on T cells and antigen-presenting cells that result in either interleukin-4-dependent or -independent immune responses. J Infect Dis 2000;182:180-90.
89. Lycke N, Severinson E, Strober W. Cholera toxin acts synergistically with IL-4 to promote IgG1 switch differentiation. J Immunol 1990;145:3316-24.
90. Marinaro M, Staats HF, Hiroi T et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol 1995;155:4621-9.
91. Bowman CC, Clemens JD. Differential biological and adjuvant activities of cholera toxin and Escherichia coli heat-labile enterotoxin hybrids. Infect Immun 2001;69:1528-35.
92. Jakobsen H, Adarna BC, Schulz D, Rappuoli R, Jonsdottir I. Characterization of the antibody response to pneumococcal glycoconjugates and the effect of heat-labile enterotoxin on IgG subclasses after intranasal immunization. J Infect Dis 2001;183:1494-500.
93. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709-60.
94. McCluskie MJ, Weeratna RD, Davis HL. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants. Vaccine 2001;19:2657-60.
95. McCluskie MJ & Davis HL. CpG DNA as mucosal adjuvant. Vaccine 1909;18:231-7.
96. Davis HL, Weeranta R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998;160:876.
97. Weeratna RD, McCluskie MJ, Xu Y, Davis HL. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 2000;18:1762.
98. Millan CLB, Weeratna R, Krieg AM, Siegrist CA, Davis HL. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci USA 1998;95:15553-8.
99. Kovarik J, Bozzotti P, Love-Homan L et al. CpG oligonucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol 1999;162:1611-7.
100. Giebink GS, Koskela M, Vella PP, Harris M, Le CT. Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: immunogenicity and efficacy in experimental pneumococcal otitis media. J Infect Dis 1993;167:347-55.
101. Giebink GS, Meier JD, Quartey MK, Liebeler CL, Le CT. Immunogenicity and efficacy of Streptococcus pneumoniae polysaccharide-protein conjugate vaccines against homologous and heterologous serotypes in the chinchilla otitis media model. J Infect Dis 1996;173:119-27.
102. van der Ven LT, van den Dobbelsteen GP, Nagarajah B et al. A new rat model of otitis media caused by Streptococcus pneumoniae. conditions and application in immunization protocols. Infect Immun 1999;67:6098-103.
103. Barbour ML, Mayon-White RT, Coles C, Crook DW, Moxon ER. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis 1995;171:93-8.
104. Sigurdardottir ST, Jonsdottir I, Gudnason T et al. Effect of 11-valent conjugated pneumococcal vaccine (Pnc) on pneumococcal colonization in children at 2 years of age, abstr. G1-86. In Programs and Abstracts of the 41th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society for Microbiology, 2001.
105. Shurin PA, Rehmus JM, Johnson CE et al. Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children. J Pediatr 1993;123:801-10.
106. Kauppi M, Eskola J, Kayhty H. Anti-capsular polysaccharide anti-body concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines. Pediatr Infect Dis J 1995;14:286-94.
107. Nurkka A, Ahman H, Korkeila M, Jantti V, Kayhty H, Eskola J. Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2001;20:25-33.
108. Nurkka A, Ahman H, Yaich M, Eskola J, Kayhty H. Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT. Vaccine 2001;20:194-201.
109. Choo S, Zhang Q, Seymour L, Akhtar S, Finn A. Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants. J Infect Dis 2000;182:1260-3.
110. Zhang Q, Pettitt E, Burkinshaw R, Race G, Shaw L, Finn A. Mucosal immune responses to meningococcal conjugate polysaccharide vaccines in infants. Pediatr Infect Dis J 2002;21:209-13.
111. Nieminen T, Kayhty H, Leroy O, Eskola J. Pneumococcal conjugate vaccination in toddlers: mucosal antibody response measured as circulating antibody-secreting cells and as salivary antibodies. Pediatr Infect Dis J 1999;18:764-72.
112. Zhang Q, Choo S, Everard J, Jennings R, Finn A. Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents. Infect Immun 2000;68:2692-7.
113. Zhang Q, Lakshman R, Burkinshaw R et al. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom. Infect Immun 2001;69:4337-41.
114. St Geme JW III. The pathogenesis of nontypable Haemophilus influenzae otitis media. Vaccine 2000;19 (Suppl. 1):S41-50.
115. Mariotti S, Teloni R, von Hunolstein C, Romagnoli G, Orefici G, Nisini R. Immunogenicity of anti-Haemophilus influenzae type b CRM197 conjugate following mucosal vaccination with oligodeoxynucleotide containing immunostimulatory sequences as adjuvant. Vaccine 2002;20:2229-39.
116. Giebink GS. Vaccination against middle-ear bacterial and viral pathogens. Ann N Y Acad Sci 1997;830:330-52.
117. Kurono Y, Yamamoto M, Fujihashi K et al. Nasal immunization induces Haemophilus influenzae-specific Th1 and Th2 responses with mucosal IgA and systemic IgG antibodies for protective immunity. J Infect Dis 1999;180:122-32.
118. Kurono Y, Shigemi H, Kodama S, Mogi G. Effects of oral and systemic immunization on nasopharyngeal clearance of nontypeable Haemophilus influenzae in BALB/c mice. Laryngoscope 1996;106:614-8.
119. Hirano T, Hou Y, Jiao X, Gu XX. Intranasal immunization with a lipooligosaccharide-based conjugate vaccine from nontypeable Haemophilus influenzae enhances bacterial clearance in mouse nasopharynx. FEMS Immunol Med Microbiol 2003;35:1-10.
120. Cutter D, Mason KW, Howell AP, Flink DL, Green BA, St Geme JW III. Immunization with Haemophilus influenzae Hap adhesin protects against nasopharyngeal colonization in experimental mice. J infect Dis 2002;186:1115-21.
121. Kurono Y, Suzuki M, Mogi G et al. Effects of intranasal immunization on protective immunity against otitis media. Int J Pediatr Otorhinolaryngol 1999;49 (Suppl. 1):S227-9.
122. Hotomi M, Saito T, Yamanaka N. Specific mucosal immunity and enhanced nasopharyngeal clearance of nontypeable Haemophilus influenzae after intranasal immunization with outer membrane protein P6 and cholera toxin. Vaccine 1998;16:1950-6.
123. Kyd JM, Dunkley ML, Cripps AW. Enhanced respiratory clearance of nontypeable Haemophilus influenzae following mucosal immunization with P6 in a rat model. Infect Immun 1995;63:2931-40.
124. Sabirov A, Kodama S, Hirano T, Suzuki M, Mogi G. Intranasal immunization enhances clearance of nontypeable Haemophilus influenzae and reduces stimulation of tumor necrosis factor alpha production in the murine model of otitis media. Infect Immun 2001;69:2964-71.
125. Tuomanen EI, Austrian R, Masure HR. Pathogenesis of pneumococcal infection. N Engl J Med 1995;11:1280-4.
126. Tuomanen EI. The biology of pneumococcal infection. Pediatr Res 1997;42:253-8.
127. Wu H, Nahm MH, Guo Y, Russel MW, Briles DE. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection and sepsis with Streptococcus pneumoniae. J Infect Dis 1997; 175:839-46.
128. Saeland E, Vidarsson G, Jonsdottir I. Pneumococcal pneumonia and bacteremia model in mice for the analysis of protective antibodies. Microb Pathog 2000;29:81-91.
129. Jakobsen H, Schulz D, Pizza M, Rappuoli R, Jonsdottir I. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Infect Immun 1999;67:5892-7.
130. Jakobsen H, Saeland E, Gizurarson S, Schulz D, Jonsdottir I. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections. Infect Immun 1999;67:4128-33.
131. Seong SY, Cho NH, Kwon IC, Jeong SY. Protective immunity of michrosphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae. Infect Immun 1999; 67:3587-92.
132. Briles DE, Hollingshead SK, Brooks-Walter A et al. The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine 2000;18:1707-11.
133. Briles DE, Ades E, Paton JC et al. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun 2000;68:796-800.
134. Balachandran P, Brooks-Walter A, Virolainen-Julkunen A, Hollingshead SK, Briles DE. Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun 2002;70:2526-34.
135. Nayak AR, Tinge SA, Tart RC, McDaniel LS, Briles DE, Curtiss R III. A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae. Infect Immun 1998;66:3744-51.
136. Arulanandam BP, Lynch JM, Briles DE, Hollingshead S, Metzger DW. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun 2001;69:6718-24.
137. Tart RC, McDaniel LS, Ralph BA, Briles DE. Trunctated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J Infect Dis 1996;173:380-6.
138. McDaniel LS, McDaniel DO, Hollingshead SK, Briles DE. Comparison of the PspA sequence from Streptococcus pneumoniae EF5668 to the previously identified PspA sequence from strain Rx1 and ability of PspA from EF5668 to elicit protection against pneumococci of different capsular types. Infect Immun 1998;66:4748-54.
139. Hvalbye BK, Aabetge IS, Lovik M, Haneberg B. Intranasal immunization with heat-inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection. Infect Immun 1999;67:4320-5.
140. Malley R, Lipsitch M, Stack A et al. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect Immun 2001;69:4870-3.
141. Baudner BC, Balland O, Giuliani MM et al. Enhancement of protective efficacy following intranasal immunization with vaccine plus LT-K63 mutant delivered with nanoparticles. Infect Immun 2002;70:4785-90.
142. Ugozzoli M, Mariani M, Del Giudice G, Soenawan E, O'Hagan DT. Combinations of protein polysaccharide conjugate vaccines for intranasal immunization. J Infect Dis 2002;186:1358-61.
143. Dalseg R, Wedege E, Holst J, Haugen IL, Hoiby EA, Haneberg B. Outer membrane vesicles from group B meningococci are strongly immunogenic when given intranasally to mice. Vaccine 1999;17:2336-45.
144. Saunders NB, Shoemaker DR, Brandt BL, Moran EE, Larsen T, Zollinger WD. Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice. Infect Immun 1999;67:113-9.
145. Haneberg B, Dalseg R, Wedege E et al. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect Immun 1998;66:1334-41.
146. Bakke H, Lie K, Haugen IL et al. Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance. Infect Immun 2001;69:5010-5.
147. Madoff LC, Paoletti LC, Tai JY, Kasper DL. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes. J Clin Invest 1994;94:286-92.
148. Wessels MR, Paoletti LC, Pinel J, Kasper DL. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Infect Dis 1995;171:879-84.
149. Shen X, Lagergard T, Yang Y, Lindblad M, Fredriksson M, Holmgren J. Group B streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization. Infect Immun 2001; 69:297-306.
150. Shen X, Lagergård T, Yang Y, Lindblad M, Fredriksson M, Holmgren J. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization. Infect Immun 2001;69:297-306.
151. Hotdnes K, Tynning T, Brown TA, Haneberg B, Jonsson R. Nasal immunization with group B streptococci can induce high levels of specific IgA antibodies in cervicovaginal secretions of mice. Vaccine 1997;15:1244-51.
152. Siegrist CA. Neonatal and early life vaccinology. Vaccine 2001;19:3331-46.
153. Mond JJ, Ottolini CMG. Prospects for vaccines during pregnancy and in the newborn period. Clin Perinatol 1997;24:231-49.
154. Siegrist CA, Plotnicky-Gilquin H, Cordova M et al. Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies. J Infect Dis 1999;179:1326-33.
155. Barrios C, Brawand P, Berney M, Brandt C, Lambert PH, Siegrist CA. Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-based pattern which persists after adult boosting. Eur J Immunol 1996;26:1489-96.
156. Jakobsen H, Bjarnarson SP, Del Giudice G, Moreau M, Siegrist CA, Jonsdottir I. Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a non toxic mutant of heat-labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice. Infect Immun 2002;70:1443-52.
157. Jakobsen H, Hannesdottir SG, Bjarnarson SP et al. Age-dependent T-cell responses to pneumococcal conjugate vaccines: a weak and Th2-biased response in neonates can be circumvented by the adjuvant LT-K63. 15th European Immunology Congress - EFIS 2003, Rhodes, Greece, 2003.